Molecular Therapies for Choroideremia

Area of Science:

• Ophthalmology
• Genetics
• Molecular Biology

Background:

• Inherited retinal diseases (IRDs) are a leading cause of blindness.
• Gene therapy has emerged as a promising treatment for IRDs, with Luxturna already approved.
• Choroideremia is a common IRD with ongoing gene therapy trials.

Purpose of the Study:

• To review clinical phenotyping and genetic testing for choroideremia.
• To update on current gene therapy trials for choroideremia.
• To discuss alternative molecular therapies for choroideremia.

Main Methods:

• Review of molecular mechanisms in choroideremia pathogenesis.
• Analysis of ongoing gene therapy clinical trials.
• Evaluation of novel therapeutic strategies including CRISPR gene editing and small molecule therapies.

Main Results:

• Gene therapy trials for choroideremia are advancing, with Phase III trials underway.
• CRISPR gene editing and nonsense suppression therapy show potential for treating choroideremia.
• Future studies may include female carriers in clinical trials.

Conclusions:

• Gene therapy is a rapidly advancing field for treating inherited retinal diseases.
• Choroideremia treatment is progressing with gene therapy and alternative molecular approaches.
• Further research is needed to optimize therapies and expand trial eligibility.